Today: 7 February 2026
Subscribe
Browse Category

Biotech News News 24 December 2025 - 30 December 2025

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands. The move keeps attention on Genmab’s pipeline as investors reassess which late-stage assets can power growth. Dropping a late-stage program can change a biotech’s outlook quickly because those trials sit closest to potential approvals and revenue. Genmab said on Monday it will discontinue further clinical development of acasunlimab after a portfolio review, citing a more competitive landscape. “After
30 December 2025
·····
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

NEW YORK, December 30, 2025, 13:14 ET — Regular session Corcept Therapeutics Inc shares fell 8.9% to $72.72 in early afternoon Nasdaq trading on Tuesday, after touching a session low of $72.26. The stock was last down $7.10 from Monday’s close, with about 897,000 shares traded. The decline comes as investors focus on Corcept on the day the U.S. Food and Drug Administration is due to decide on relacorilant, its experimental treatment for endogenous hypercortisolism, also known as Cushing’s syndrome. Under the Prescription Drug User Fee Act, or PDUFA, the FDA sets a target date for taking action on a
30 December 2025
·····
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

NEW YORK, December 30, 2025, 12:33 ET — Regular session Edgewise Therapeutics shares were up 0.2% at $24.68 as of 12:18 p.m. ET on Tuesday, after a Form 144 filing showed company officer Robert Michael Carruthers sold 116,665 shares worth about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92. SEC The disclosure matters because Edgewise is a development-stage biotech, where trading often centers on clinical milestones and cash runway rather than product sales. Insider transactions can draw outsized attention after sharp moves, even when the dollar amounts are modest. Biotech stocks also lagged, with the iShares
30 December 2025
·····
Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

NEW YORK, December 29, 2025, 10:35 ET Live Oak Private Wealth LLC cut its stake in Pfizer (PFE.N) by 92.5% in the third quarter, selling 216,868 shares and ending the period with 17,627 shares, a regulatory filing showed. MarketBeat+2SEC+2 The disclosures matter because quarterly holdings reports are one of the few windows investors get into how money managers were positioned in major stocks heading into the final stretch of the year. The filings can signal shifting conviction in Pfizer, a high-profile name in U.S. healthcare. MarketBeat+2MarketBeat+2 The reports are known as Form 13F filings, which large investment managers submit to
29 December 2025
·····
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

NEW YORK, December 28, 2025, 20:34 ET — Market closed Eli Lilly shares ended the holiday week little changed after South Korean biotech ABL Bio said it would receive $55 million in funding from the U.S. drugmaker under a research collaboration. PR Newswire The funding is small by Lilly standards, but it underscores how closely investors are tracking the company’s dealmaking and research spending as it looks to extend growth beyond its blockbuster diabetes and obesity franchise. PR Newswire That focus has sharpened into year-end as traders look ahead to 2026, when regulatory decisions and clinical readouts across Lilly’s obesity
29 December 2025
·····
Regencell Bioscience (RGC) Stock: What to Know After a Sharp Friday Slide, Latest Headlines, and the Setup for Monday

Regencell Bioscience (RGC) Stock: What to Know After a Sharp Friday Slide, Latest Headlines, and the Setup for Monday

NEW YORK, Dec. 27, 2025, 7:48 PM ET — Market closed Regencell Bioscience Holdings Limited (Nasdaq: RGC) is heading into the final trading stretch of 2025 under a brighter spotlight after a volatile week capped by a steep Friday drop—one that stood out even as the broader U.S. market barely moved in a quiet, post-Christmas session. RGC last closed at $21.16 on Friday, Dec. 26, down $3.44 (-13.98%) on the day, according to delayed consolidated market data. FinancialContent+1 That decline followed an active December that has featured wide swings: RGC traded between $20.50 and $24.31 during Friday’s session, while the
28 December 2025
·····
Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday

Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday

NEW YORK, Dec. 27, 2025, 6:40 a.m. ET — Market closed Regencell Bioscience Holdings Limited (NASDAQ: RGC) stock heads into the weekend after a sharp Friday pullback, closing at $21.16, down 13.98% from the prior close of $24.60, in a move that put the name on multiple “top losers” radars as U.S. markets wrapped up a quiet post-Christmas session. aaii.com+2Investing.com+2 The late-week decline lands amid a broader backdrop that investors have come to associate with RGC in 2025: outsized percentage swings, intermittent liquidity, and a trading narrative that can move faster than traditional biotech fundamentals. In fact, AAII’s market-close recap
27 December 2025
····
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

NEW YORK — Friday, December 26, 2025 (1:07 p.m. ET). U.S. stocks are trading in a post-holiday session with major benchmarks close to flat, while biotech is notably weaker. Against that backdrop, Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is pulling back after a sharp midweek move tied to a clinical update in hypertrophic cardiomyopathy (HCM). As of the latest trade captured around 12:55 p.m. ET, EWTX traded near $26.00, down about 4.7% on the day, with an intraday range of $25.40 to $27.92 and volume above 1.0 million shares. EWTX price action in today’s market: biotech pressure meets profit-taking Today’s tape
26 December 2025
·····
Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

Regencell Bioscience (RGC) Stock Drops in Thin Post‑Christmas Trading as DOJ Probe and “Going Concern” Warning Keep Risk Front and Center

New York time check: It is Friday, December 26, 2025, 12:17 p.m. ET in New York. While the broader U.S. market is mostly drifting near record territory in subdued post‑holiday volume, Regencell Bioscience Holdings Limited (Nasdaq: RGC) is doing what it’s become famous for in 2025: moving a lot, on not much liquidity. AP News As of the most recently available intraday quote in late morning trading, RGC was around $21.28, down roughly 13.5% on the day, with a wide intraday range (roughly $20.71–$24.47) and relatively light volume—conditions that can exaggerate price swings in either direction. What’s happening with RGC
26 December 2025
··
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is down about 1.07% and iShares Nasdaq Biotechnology ETF (IBB) is down about 0.63%—even as the broader market edges higher, with SPY and QQQ both modestly in the green. That “WVE down while the market is up” headline can look ominous—until you zoom out and remember what happened earlier this month: Wave’s stock ripped higher on early obesity data, then the
26 December 2025
·····
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation (NASDAQ: OMER) is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to see. As of 2:35 p.m. ET in after-hours trading on Wednesday, Dec. 24, 2025, OMER stock traded around $15.36, up about $6.59 (+75%) from the prior close, after swinging through a wide intraday range on heavy volume. This move matters not only because it’s dramatic — it’s because it’s tied to a hard catalyst: FDA approval of YARTEMLEA (narsoplimab‑wuug) for
24 December 2025
·····
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI (sparsentan) and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis+2New York Stock Exchange+2 TVTX stock action on Dec. 24, 2025: a thin-session breakout with big numbers In early trading on Dec. 24, TVTX was up roughly 15% and changing hands around the low $40 range—an outsized move for a single session,
24 December 2025
·····
1 … 4 5 6 7 8 … 12

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop